Anti Small Ubiquitin-Related Modifier 2 (SUMO2) and Small Ubiquitin-Related Modifier 3 (SUMO3) mAb (Clone 3H12)

Cosmo Bio LTD

Catalog No: CAC-CEC-044

• 
• 

Visit our Neurodegeneration Products homepage to browse related research products

Catalog numbers beginning with "CAC" are antibodies from our exclusive Cosmo Bio Antibody Collection. Visit the CAC Antibody homepage to browse the collection list, organized by research topic.

Click here to view Ubiquitin-Proteasome Research Related Products from Cosmo Bio
Application: ICC, IHC, WB, IF 
Clonality: Monoclonal 
Host: Rat 
Purification: IgG, Ion-exchange Chromatography, Gel Filtration 
Reactivity: Monkey, Mouse, Rat, Human 

SUMOylation is a reversible post-translational modification which has emerged as a crucial molecular regulatory mechanism, involved in the regulation of DNA damage repair, immune responses, carcinogenesis, cell cycle progression and apoptosis. Four SUMO isoforms have been identified, which are SUMO1, SUMO2/3 and SUMO4. The small ubiquitin-like modifier (SUMO) pathway is conserved in all eukaryotes and plays pivotal roles in the regulation of gene expression, cellular signaling and the maintenance of genomic integrity. The SUMO catalytic cycle includes maturation, activation, conjugation, ligation and de-modification. The dysregulation of the SUMO system is associated with a number of diseases, particularly cancer. SUMOylation is widely involved in carcinogenesis, DNA damage response, cancer cell proliferation, metastasis and apoptosis. SUMO can be used as a potential therapeutic target for cancer. [from: Han ZJ, Feng YH, Gu BH, Li YM and Chen H. (2018) The post-translational modification, SUMOylation, and cancer (Review). International Journal Of Oncology. 52:1081-1094.]

References:
1) Saitoh et al. (2006). Exp Cell Res. 312:1418-1430. This reference uses the antibody.